- Summit Therapeutics said the admission of new shares in the company connected with its proposed $25m capital raising was expected to occur on or around this Wednesday.

The admission to AIM was for around 78.1m new shares in the form of around 15.6m American depository shares.

At 8:09am: [LON:SUMM] Summit Therapeutics PLC share price was +2.5p at 25.5p

Story provided by